Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
These 2 moon rovers used cameras and lasers to hunt for simulated water ice — and one looks like WALL-E - 2Figure out how to Amplify Your Open Record Reward
- 3Individual Preparation Administrations to Raise Your Wellness Process
- 4Addiction-stricken community struggles to keep a syringe program going after Trump's order
- 5Invigorating Spots To Go Kayaking All over The Planet
- Forget 'Outer Banks.' These Gen Z-ers just want to watch 'M*A*S*H*' and 'Gilmore Girls.'
- Instructions to Distinguish the Wellbeing Dangers Related with 5G Pinnacles
- German-Polish man charged with calling for attacks on top politicians
- Industrial zone damaged in Negev, falls in Sharon area after Iran fires missiles towards Israel
- Tehran synagogue damaged by missile strike according to Iranian media
- Find Successful Magnificence Items for Sparkling Skin
- From Representative to Business visionary: Private issue Victories
- A new mom skipped a routine appointment. An infected cut led to a devastating diagnosis
- A photographer's journey to capture a blood moon rising over the South China Sea. 'It was an incredible moment'
